The revascularization of tibial arteries in patients with critical lower limb ischemia using drug-coated balloons vs. conventional angioplasty resulted in comparable long-term outcomes in terms of both safety and efficacy.
Paclitaxel exposure was not related to a higher risk of amputation or all-cause mortality at 5 years (which is the good news for much questioned drug-coated balloons). The problem is that the aforementioned devices have not shown higher efficacy than conventional angioplasty in this disease, but they do entail a significant increase in costs.
IN.PACT DEEP was a prospective, randomized, multicenter trial that enrolled 358 patients with critical lower limb ischemia.
Read also: Another Scandal in Evidence-Based Medicine: Ambulatory BP Monitoring Questioned?
After a 5-year follow-up, freedom from clinically driven revascularization was 70.9% and 76%, and the safety composite endpoint (revascularization, amputation, and all-cause mortality) was 59.8% and 57.5% for the drug-coated balloon group vs. the conventional group, respectively.
Given the recent concern regarding mortality, there was a specific analysis addressing this issue. Paclitaxel was not associated with mortality in any dose tercile.
Conclusion
Paclitaxel-coated balloons and conventional balloons used in infrapopliteal angioplasty in patients with critical ischemia resulted in comparable long-term safety and efficacy. There was no association observed between paclitaxel and the risk of amputation or death at 5 years.
Original title: The IN.PACT DEEP Clinical Drug-Coated Balloon Trial 5-Year Outcomes.
Reference: Thomas Zeller et al. J Am Coll Cardiol Intv 2020;13:431–43.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.